article_metadata: W J Mullally F J Cooke I M Crosbie S Kumar V E Abernethy E J Jordan M O'Connor A M Horgan R Landers J Naidoo P M Calvert
article_metadata: 10.3389/fimmu.2022.871217
article_metadata: Front Immunol
article_metadata: 2022 Apr 20;13:871217.
article_metadata: combination checkpoint inhibitors hematological adverse events ipilimumab nivolumab thrombotic-thrombocytopenic purpura
article_metadata: CC BY
article_metadata: https://pubmed.ncbi.nlm.nih.gov/35514990/
article_metadata: Melanoma / drug therapy Neoplasms, Second Primary Purpura, Thrombocytopenic, Idiopathic Purpura, Thrombotic Thrombocytopenic / diagnosis
article_metadata: Melanoma / drug therapy Neoplasms, Second Primary Purpura, Thrombocytopenic, Idiopathic Purpura, Thrombotic Thrombocytopenic / diagnosis Case Reports Humans Immunologic Factors Immunotherapy Ipilimumab / adverse effects Male Nivolumab / adverse effects Immunologic Factors Ipilimumab Nivolumab
article_metadata: PMC9067158
article_metadata: 35514990
article_metadata: Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma
article_metadata: 2022